Home/Pipeline/Sotrovimab

Sotrovimab

COVID-19

AuthorizedMarketed (with GSK)

Key Facts

Indication

COVID-19

Phase

Authorized

Status

Marketed (with GSK)

Company

Vir Biotechnology

About Vir Biotechnology

Vir Biotechnology is a San Francisco-based immunology company with a mission to power the immune system to transform patient lives. Founded in 2016, the company has rapidly validated its technology platforms through successful COVID-19 and Ebola programs and is now strategically focused on high-unmet-need areas, including chronic hepatitis delta and select oncology indications. Its strategy combines deep immunology expertise with advanced antibody engineering to create differentiated, rapidly deployable clinical candidates.

View full company profile

Therapeutic Areas

Infectious Diseases Oncology

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
PanCytoVir™ (oral probenecid)	TrippBio	Phase 2	Active
OT-101	Sapu BioScience	Clinical Trial (Phase not specified)	Active
Idylla SARS-CoV-2 Test	Biocartis	Approved	CE-IVD
COVID-19 Vaccine Testing (for AstraZeneca)	Advaxia Biologics	Approved	Active
COVID-19 Vaccine Clinical Batches	Advaxia Biologics	Clinical	Active
UOL COVID-19 Test	Uh-Oh Labs	Approved	Active
Lagevrio (molnupiravir)	Ridgeback Biotherapeutics	Approved/EUA	Active
CVXGA	CyanVac	Phase 2	Active
SARS-CoV-2 Test	NanoPin Technologies	Commercial (LDT)	Active
Emeramide for COVID-19	EmeraMed	Preclinical	Active
COVID-19 Oral Therapeutic (with Sen-Jam Pharmaceutical)	KVK Tech	Development	Active